Join Scrip editors Mandy Jackson and Mary Jo Laffler and Pink Sheet senior writer Sarah Karlin-Smith in this free access audio podcast on the recent BIO International Convention in Boston.
The discussion covers the general mood around the current US economic and policy environment, the dismissal of the US ACIP vaccine panel, the climate for deals and financing, the rise of China’s biopharma industry and other key topics from the meeting.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Time Stamps
0:45 Economic and policy environment in the US.
2:50 BIO leadership surprisingly open about the industry’s challenges, and willingness to call out Trump government.
4:20 Most-favored nation policy proposal: storm in a teacup or existential threat?
7:57 DTC sales: new opportunities to sidestep middlemen? GLP-1s leading the way.
10:52 Impact of FDA staff cuts and changes on regulatory practices and policy, and on biopharma companies.
16:47 Reaction of vaccine companies, health providers, insurers and other stakeholders to ACIP panel dismissal and policy uncertainty.
22:27 Climate for biopharma dealmaking and financing; demand for assets.
27:28 Advice for startups in challenging times.
29:49 China’s biopharma industry in the ascendant.
33:27 Rare diseases policy, regulation and industry focus.
38:15 Priorities for BIO.
